Abstract
Renal cell carcinoma (RCC) is a malignant tumor of the renal tubular epithelial cells with a relatively high incidence rate worldwide. A large number of studies have indicated that dysregulation of the ubiquitination, including ubiquitination and dysregulation, is associated with the occurrence and development of RCC. This review focuses on several abnormal signaling pathways caused by E3 ligases and deubiquitinases. Additionally, we discuss research progress in RCC treatment by targeting key enzymes related to ubiquitination modifications.
Keywords:
E3 ubiquitin ligases; PROTAC; deubiquitinase; immunotherapy; renal cell carcinoma (RCC); ubiquitination.
Copyright © 2024 You, Zhang, Jin and Yan.
Grants and funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by The National Natural Science Foundation of China (grant no. 32270821), the Natural Science Foundation of Ningbo (grant no. 2021J065), the Youth Science and Technology Innovation Leader of Ningbo (grant no. 2023QL052), the K.C. Wong Magna Fund in Ningbo University, the Ningbo Clinical Research Center for Urological Disease (grant no. 2019A21001), the Ningbo Top Medical and Health Research Program (grant no. 2022020203), the Zhejiang Engineering Research Center of Innovative Technologies, and diagnostic and therapeutic equipment for urinary system diseases.